Cardiovascular AgentsCoreg (carvedilol)
Drug Approval Classification: Supplemental New Drug Application (Approval Date: 03/28/03)
New Indication: Coreg (carvedilol) is indicated for the treatment of patients with left ventricular dysfunction following myocardial infarction.
Coreg is also indicated for the treatment of essential hypertension.
Clinical Summary: CAPRICORN (CArvedilol Post InfaRction SurvIval COntRol in Left Ventricular DysfunctioN) trial -- a multinational, multicenter, randomized, double-blind, parallel group study in patients with left ventricular systolic dysfunction following a recent acute myocardial infarction -- evaluated the efficacy of carvedilol. A total of 1949 patients were randomized to carvedilol 6.25 mg twice daily or placebo and followed for a mean of 15 months. Ninety-eight percent of patients on study took an angiotensin II converting enzyme inhibitor. The risk of death was 23% lower for patients on carvedilol compared with placebo.
Medscape Pharmacists. 2003;4(1) © 2003 Medscape
Cite this: April 2003 - Medscape - Apr 23, 2003.